1. Traitements aggravant une infection par le COVID-19 : vraiment ? [Drugs that aggravate the course of COVID-19 : really ?]
- Author
-
Rothuizen, L.E., Livio, F., and Buclin, T.
- Subjects
Adrenal Cortex Hormones/administration & dosage ,Adrenal Cortex Hormones/adverse effects ,Angiotensin-Converting Enzyme Inhibitors/administration & dosage ,Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ,Anti-Inflammatory Agents, Non-Steroidal/adverse effects ,Betacoronavirus ,Coronavirus Infections/complications ,Coronavirus Infections/epidemiology ,Humans ,Pandemics ,Pneumonia, Viral/complications ,Pneumonia, Viral/epidemiology - Abstract
The safety of NSAIDs, corticosteroids and renin-angiotensin inhibitors in COVID-19 is challenged. NSAIDs may interfere with the defense process against viral infection and are best avoided. Systemic corticosteroids have not shown benefit in viral infection, including other coronavirus; thus they should be avoided, unless prescribed for another indication. The benefit-risk ratio is however clearly in favor of continuing inhaled corticosteroids in patients with asthma or COPD. ACE inhibitors and sartans upregulate the expression of angiotensin-converting enzyme 2 (ACE2), the pulmonary receptor for SARS-CoV-2. Any possible clinical impact of these treatments on COVID-19 infection remains to be clarified; in the meantime, they should be continued.
- Published
- 2020